INTERCEPT Blood System for Red Blood Cells
Pathogen reduction for red blood cell transfusions
Late-Stage Clinical DevelopmentIn Phase 3/clinical evaluation (e.g., INITIATE study)
Key Facts
Indication
Pathogen reduction for red blood cell transfusions
Phase
Late-Stage Clinical Development
Status
In Phase 3/clinical evaluation (e.g., INITIATE study)
Company
About Cerus
Cerus Corporation is dedicated to becoming the preeminent global blood products company by safeguarding the world's blood supply through its INTERCEPT pathogen reduction technology. The company has achieved significant commercial traction with its FDA and CE-marked systems for platelets and plasma, and its U.S.-approved INTERCEPT Fibrinogen Complex. Its strategic focus is on expanding the INTERCEPT platform to all major blood components, most critically red blood cells, while driving global adoption through partnerships with blood centers and health authorities.
View full company profile